shortagewatch

Home / Companies / Opella

Company family · HQ FR

Opella: medicine shortages

Sanofi consumer health spin-off (majority owned by CD&R)

As of 2 Nov 2026, 8 Opella products have a reported shortage across 6 countries, covering 6 medicines.

Products short8rank #223 of 464
Medicines6active ingredients
Countries6/16
New in 90 days4+2 vs market pace
Typical duration3 monthsmedian so far
Manufacturing83%demand-driven 17%

Where

Italy1Spain1Belgium1Czechia3Norway1Sweden1

Which therapeutic classes

Digestive tract and metabolism4Respiratory system2Musculoskeletal system1Nervous system1

Why, compared with all companies

Manufacturing problemIncreased demandActive ingredient shortageDistribution or logisticsCommercial decision or withdrawalRegulatory or licensingOtherNot stated
OpellaOpella: Manufacturing problem 5 (62%)62%Opella: Increased demand 1 (12%)12%Opella: Not stated 2 (25%)25%All companiesAll companies: Manufacturing problem 4,896 (36%)36%All companies: Increased demand 1,873 (14%)14%All companies: Active ingredient shortage 367 (3%)All companies: Distribution or logistics 336 (2%)All companies: Commercial decision or withdrawal 435 (3%)All companies: Regulatory or licensing 131 (1%)All companies: Other 1,244 (9%)9%All companies: Not stated 4,220 (31%)31%

Manufacturing problems point to the company's own supply chain; increased demand often follows a competitor's shortage or a demand shock.

Latest changes

All changes

No changes recorded yet. Changes are tracked from our daily snapshots.

Open shortages over time

233431 Oct2026-10-31: 31 Nov2026-11-01: 32 Nov2026-11-02: 3

Products short per day in the 5 countries tracked since 31 Oct 2026, from our daily snapshots. The history lengthens every day.

When its current shortages began

01235Dec: 0Jan ’25: 0Feb: 0FebMar: 0Apr: 0May: 0MayJun: 0Jul: 0Aug: 0AugSep: 0Oct: 0Nov: 0NovDec: 0Jan ’26: 0Feb: 0FebMar: 0Apr: 0May: 0MayJun: 1Jul: 0Aug: 1AugSep: 0Oct: 3Nov: 0Nov

Against its peers

Viatris995Teva903Sandoz603Pfizer491Accord (Intas)484Stada349Zentiva340Fresenius Kabi339Apotex326Sun Pharma250Aurobindo226Towa (Pensa)201Krka187Sanofi158Opella8

Breadth vs depth

1101001,00010,0001101001,000Products short (log scale)Medicines affected (log scale)Viatris: 995 / 248ViatrisTeva: 903 / 289TevaSandoz: 603 / 198SandozPfizer: 491 / 122PfizerAccord (Intas): 484 / 151Accord (Intas)Stada: 349 / 140Zentiva: 340 / 159ZentivaFresenius Kabi: 339 / 81Apotex: 326 / 152Sun Pharma: 250 / 77Aurobindo: 226 / 111Towa (Pensa): 201 / 102Krka: 187 / 67Sanofi: 158 / 45Jamp: 150 / 73Baxter: 149 / 27Sawai: 148 / 68Hikma: 126 / 44Glenmark: 105 / 39Sanis: 98 / 54Cheplapharm: 86 / 28GSK: 85 / 38Advanz (Amdipharm): 81 / 24Nichi-Iko: 77 / 29Takeda: 76 / 10Johnson & Johnson: 75 / 19Neuraxpharm: 75 / 19Novartis: 70 / 32Bayer: 68 / 17Biomed: 64 / 21Daiichi Sankyo: 59 / 18Orifarm: 59 / 40Medochemie: 56 / 14Pharmascience: 51 / 32Marcan: 51 / 16Doc Generici: 50 / 25B. Braun: 49 / 17AA Pharma: 46 / 26H E: 46 / 15Octapharma: 42 / 6Jv E: 42 / 1Kyowa Pharmaceutical: 42 / 16Novo Nordisk: 41 / 8Odan: 41 / 31Aspen: 41 / 13Sterop: 41 / 16Nipro: 41 / 17Dr. Reddy's: 40 / 24Organon: 40 / 20Laboratoire Riva: 40 / 23Kern Pharma: 40 / 30Bausch Health: 39 / 30Bracco: 38 / 6G.L.: 38 / 13Tatsumi Kagaku: 38 / 24Otsuka: 37 / 4Eli Lilly: 37 / 12Piramal Critical: 35 / 13Imuna Pharm: 35 / 4AbbVie: 34 / 15Medical Valley: 34 / 8Orion: 34 / 24Rowex: 34 / 19Takata Pharmaceutical: 33 / 17Aristo: 32 / 16Norgine: 32 / 3Gedeon Richter: 31 / 11Eql: 31 / 9Guerbet: 30 / 5Lukas Heil-Betriebsst: 30 / 0Roche: 29 / 14Omega: 29 / 18Bgp: 29 / 18Holsten -: 29 / 3Menarini: 29 / 17Paladin: 28 / 17Grifols: 28 / 9Ge: 28 / 6Merck & Co. (MSD): 27 / 14Ferring: 27 / 7Opella: 8 / 6Opella

Further right: more products short. Higher: more different medicines affected.

Medicines short

Download CSV
MedicineWhere this company is shortProductsEarliest startMain reasonShort anywhere
Butylscopolamine218 Aug 2026Manufacturing problem3/16
Bromhexine127 Sep 2024Not stated1/16
Butylscopolamine and Analgesics127 Feb 2023Not stated1/16
Fexofenadine117 Jan 2023Manufacturing problem3/16
Ibuprofen119 Oct 2026Manufacturing problem8/16
Paracetamol, Combinations excl. Psycholeptics119 Oct 2026Manufacturing problem5/16

Shortage data describes supply, not company finances. A shortage can mean lost sales for the supplier or extra demand for its competitors. Nothing here is investment advice; tickers are for identification only and may be out of date.